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Common Thread in the Process
o Provide Optimal Heart Failure Care*
onathan G. Howlett, MD, FRCPC, FACC
algary, Alberta, Canada
Habit is habit and not to be flung out of the window by any
man but coaxed down-stairs a step at a time.
Mark Twain, from Pudd’nhead Wilson’s calendar (1)
he clinical syndrome of heart failure (HF) is associated
ith a high morbidity and mortality and accounts for a huge
nd increasing health care burden (2). Fortunately, many
herapeutic advances have become available for treatment of
his disorder, particularly for those with left ventricular
ystolic dysfunction. Unfortunately, the discovery of new
nd efficacious HF treatments has not been swiftly followed
y universal adoption in the population at large (3). In an
ttempt to provide benchmarks for HF treatment, recom-
endations for the management of patients with HF were
ublished as early as 1994 (4). Soon afterward, it became
pparent that treatment of HF did not change as a result of
ublication of these guidelines (5–7). These results are
onsistent with data showing that health care practitioners
end to overestimate the degree to which they adhere to
uideline-based therapy (8).
See page 416
In addition to publication, guidelines must be relevant,
nformative, clear, and implementable. There must be a
issemination and implementation plan that follows basic
rinciples of adult learning and quality control (9). Inter-
entions might include elements of but are not limited to
cademic detailing, interactive workshop or learning pro-
rams, practical aids for clinical practice such as pocket or
eb-based reference guides, and individual practice chart
udits. Common to these interventions is the requirement
hat there be an understanding of end-user needs and
ransparent performance feedback for individuals and insti-
utions (10).
Evaluation of the impact of these interventions has also
een problematic. Studies of guideline implementation have
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thea
merican College of Cardiology.
From Cardiac Sciences, University of Calgary, Calgary, Alberta, Canada.uffered from design flaws such as lack of randomized
ontrol groups and nonuniform distribution of clinical charac-
eristics in the cohort groups. This has prompted critics to
uggest that subsequent improvements in clinical care would
ave occurred anyway and are not due to the intervention in
uestion.
Despite these difficulties many professional organizations
ontinue to develop programs of which a central component
s the regular provision of feedback to health care practitio-
ers. The Canadian Cardiovascular Society has embarked
n a 5-year HF guidelines update and implementation
trategy, which includes an Access to Cardiac Care and
ational Workshop Initiative (11,12), conducting user
eeds assessment, and a grassroots dissemination strategy.
he measurement phase is to follow. The American Heart
ssociation Get With The Guidelines (GWTG) program,
egun in 2000, is a voluntary, national, prospective, obser-
ational data collection and quality control initiative relating
o ischemic heart disease (13). Performance measures were
ased upon the Joint Commission and Centers for Medicare
nd Medicaid (CMS) criteria and, for the most part, are
idely validated (14). In 2005, participating hospitals began
o collect data relative to HF and this year began to report
hese data publicly. This program has benefited from the
act that hospitals must report many of these performance
easures for reimbursement by CMS for care provided to
atients.
Findings from GTWG illustrate it is possible to achieve
igh rates of evidence-based therapy, although unexplained
isparity still exists between practices for many therapies,
ncluding implantable cardioverter-defibrillator (ICD) and
iventricular pacemaker therapy (15).
Recent reports describe a relatively low rate of ICD usage
or primary prevention of sudden death in eligible patients
ith HF, including large differences in application of ICD
herapy in Europe versus North America (16). Early data
uggest that differences in patient characteristics such as
egion of residence, race, insurance coverage, and age exist
etween those implanted with ICD and those not (15).
lthough patient characteristics in part explain therapeutic
isparity, we do not, for the most part, understand why they
xist. Perhaps then, factors outside of the individual patient
rofile, such as provider, institution, and system factors play
n important role.
In this issue of the Journal, Shah et al. (17) shed much-
eeded light into this aspect of treatment disparity by
eporting data from 134 U.S. hospitals participating in the
WTG Heart Failure registry. Similar to previous investi-
ators, they report a low overall rate of application of ICD
n 10,148 a priori defined eligible patients (20%), with rates
anging from 1% to over 35% in the highest tertile. They go
urther to describe “hospital characteristics” associated with
pplication of ICD therapy and note that hospitals with
igher ICD usage rates were more likely to offer other
dvanced therapies such as percutaneous coronary interven-
t
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Optimal HF Care February 3, 2009:423–5ion, coronary artery bypass grafting, and heart transplant,
ad larger bed sizes, and were more likely to have an
cademic affiliation. They also noted that higher ICD-rate
ospitals were more likely to be adherent to “newer”
erformance measures of beta-blocker, aldosterone antago-
ist, and hydralazine-nitrate therapy. Both high- and low-
CD tertile hospitals had similarly high performance in
older” measures such as angiotensin-converting enzyme or
ngiotensin receptor blocker therapy use as well as discharge
nstructions and smoking cessation advice. Finally, the
uthors note that the variation in older, simpler perfor-
ance measures, such as drug therapy, was much smaller
han the 30-fold variation in the newer, more complex
ntervention of ICD implantation.
For the first time, we get a glimpse into the characteristic
ospital more likely to adopt newer evidence-based HF
herapies. These data are important and relevant to health
are, because the method of data collection is well-validated
nd can be used for comparison purposes with any U.S.
ospital reporting similar data (14). The authors targeted
nly those cases that, according to documented clinical
riteria, would be clearly eligible for ICD therapy (14). They
xcluded those with existing ICDs and those with contra-
ndications, including any documented physician or patient
eason or refusal. Hospitals without reported procedures
nd those with 10 ICD eligible patients were excluded.
nly data with a high level of completeness were used in the
nalyses. Data quality was reviewed on a regular basis, and
atient case-mix adjustment was performed in attempts to
imit the effect of differential patient characteristics on the
esults.
This study is not without limitations. Participating hos-
itals in the GWTG program might be more likely to be
early adopters” and might not be representative of all
ospitals. The chart auditors had to rely on the quality of
ocumentation, and therefore undocumented reasons for
on-ICD implantation were not collected, serving to reduce
he level of performance measure adherence (18). Many
enters might prefer to avoid the unstable hospitalized
atient or even avoid referring to implanting centers (if they
o not have that capability themselves). These issues might
ot have been documented. And, as the authors point out,
ncreasing levels of detail regarding hospital characteristics
uch as procedure space and availability of adequately
rained medical personnel (especially referring and implant-
ng physicians) and other infrastructure were not available.
From a practical point of view, we would expect applica-
ion of newer therapies for any condition to lag behind that
f older proven therapies. Variability in the perceived value
f intervention, even when recommended, will affect appli-
ation rate. However, as Shah et al. (17) allude to, applica-
ion of “high end” device therapy might differ in several ways
rom that of medical therapy. For example, in addition to
he resources and infrastructure required to implant ICDs,
ollow-up of the patient with an ICD requires specially
rained medical personnel and equipment, and processesust be in place for the possibility for device recalls and
enerator replacements. If these resources are not also
vailable, application rates might not increase. Furthermore,
ewer devices possess hemodynamic monitoring capabilities
hat will likely have impact on the management of HF
atients (whose primary condition is HF, not arrhythmia).
his will require even more careful coordination and team-
ork from health care providers, with clearly defined roles.
ndeed, the European Society of Cardiology and Heart
hythm Society have recently published guidelines for
ollow-up of patients with implantable monitoring devices,
section of which includes the roles and responsibilities for
roviders (19).
Issues such as these and cost/benefit must be addressed as
art of future implementation process, including those
ponsored by national organizations (20). This might lead
o representation of stakeholders such as patients and health
are administrators on guideline committees. Many unan-
wered questions remain. What other system and health
are provider characteristics, such as physician bias, infra-
tructure, and cost, are associated with reduced application
f ICD therapy? How should we otherwise best identify
arriers to and support of applications of evidence-based
are in HF patients? Should we encourage only certain
ealth care institutions to provide ICD implantation, as is
he case in heart transplantation? Who should provide these
upports, and who should monitor or enforce new initia-
ives? How well do our performance measures stack up in
espect to real-world patient outcomes? What is the best
ethod for reporting care and outcomes?
Despite many unanswered questions, it is clear that
ollection of performance data with feedback to health care
ractitioners is essential to provide a basis for further study
nd intervention. Shah et al. (17) have provided a valuable
iece of the puzzle that will enable us to take 1 more step
oward optimal application of evidence-based HF therapy.
eprint requests and correspondence: Dr. Jonathan G. Howlett,
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